[1] A.I. Qureshi, L.R. Caplan, Intracranial atherosclerosis, The Lancet 383 (2014) 984–998. https://doi.org/10.1016/S0140-6736(13)61088-0.
[2] C.A. Holmstedt, T.N. Turan, M.I. Chimowitz, Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment, The Lancet Neurology 12 (2013) 1106–1114. https://doi.org/10.1016/S1474-4422(13)70195-9.
[3] J.S. Kim, D. Bonovich, Research on intracranial atherosclerosis from the East and west: why are the results different?, J. Stroke 16 (2014) 105–113. https://doi.org/10.5853/jos.2014.16.3.105.
[4] K. Ritz, N.P. Denswil, O.C.G. Stam, J.J. van Lieshout, M.J.A.P. Daemen, Cause and mechanisms of intracranial atherosclerosis, Circulation 130 (2014) 1407–1414. https://doi.org/10.1161/CIRCULATIONAHA.114.011147.
[5] Y. Qian, Y. Pu, L. Liu, D.Z. Wang, X. Zhao, C. Wang, Y. Wang, G. Liu, Y. Pan, Y. Wang, Low HDL-C level is associated with the development of intracranial artery stenosis: analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) study, PLoS ONE 8 (2013) e64395. https://doi.org/10.1371/journal.pone.0064395.
[6] J. Wu, Q. Zhang, H. Yang, X. Gao, Y. Zhou, A. Wang, C. Wang, S. Zhang, S. Wu, X. Zhao, Association between non-high-density-lipoprotein-cholesterol levels and the prevalence of asymptomatic intracranial arterial stenosis, PLoS ONE 8 (2013) e65229. https://doi.org/10.1371/journal.pone.0065229.
[7] Y. Shen, J. Wang, J. Wu, W. Qu, C. Wang, X. Gao, Y. Zhou, A. Wang, S. Wu, X. Zhao, Elevated plasma total cholesterol level is associated with the risk of asymptomatic intracranial arterial stenosis, PLoS ONE 9 (2014) e101232. https://doi.org/10.1371/journal.pone.0101232.
[8] Y.-S. Kim, J.-W. Hong, W.-S. Jung, S.-U. Park, J.-M. Park, S.-I. Cho, Y.-m. Bu, S.-K. Moon, Gender differences in risk factors for intracranial cerebral atherosclerosis among asymptomatic subjects, Gend. Med. 8 (2011) 14–22. https://doi.org/10.1016/j.genm.2011.01.001.
[9] J.-H. Park, K.-S. Hong, E.-J. Lee, J. Lee, D.-E. Kim, High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis, Stroke 42 (2011) 3040–3046. https://doi.org/10.1161/STROKEAHA.111.620104.
[10] D.-E. Kim, J.-Y. Kim, S.-W. Jeong, Y.-J. Cho, J.-M. Park, J.-H. Lee, D.-W. Kang, K.-H. Yu, H.-J. Bae, K.-S. Hong, J.-S. Koo, S.-H. Lee, B.-C. Lee, M.-K. Han, J.-H. Rha, Y.-S. Lee, G.-M. Kim, S.-L. Chae, J.S. Kim, S.U. Kwon, Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study, Stroke 43 (2012) 1824–1830. https://doi.org/10.1161/STROKEAHA.112.653659.
[11] M. Enomoto, H. Adachi, Y. Hirai, A. Fukami, A. Satoh, M. Otsuka, S.-I. Kumagae, Y. Nanjo, K. Yoshikawa, E. Esaki, E. Kumagai, K. Ogata, A. Kasahara, E. Tsukagawa, K. Yokoi, K. Ohbu-Murayama, T. Imaizumi, LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone, J. Lipids 2011 (2011) 549137. https://doi.org/10.1155/2011/549137.
[12] L.-F. Hong, X.-N. Yan, Y. Fan, Q. Wu, S.-H. Luo, B. Yang, J.-J. Li, Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores, J. Geriatr. Cardiol. 12 (2015) 402–409. https://doi.org/10.11909/j.issn.1671-5411.2015.04.012.
[13] A.R. Byun, S.W. Lee, H.S. Lee, K.W. Shim, What is the most appropriate lipid profile ratio predictor for insulin resistance in each sex? A cross-sectional study in Korean populations (The Fifth Korea National Health and Nutrition Examination Survey), Diabetol. Metab. Syndr. 7 (2015) 59. https://doi.org/10.1186/s13098-015-0051-2.
[14] M. Abbasian, M. Delvarianzadeh, H. Ebrahimi, F. Khosravi, Lipid ratio as a suitable tool to identify individuals with MetS risk: A case- control study, Diabetes Metab. Syndr. 11 Suppl 1 (2017) S15-S19. https://doi.org/10.1016/j.dsx.2016.08.011.
[15] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486–2497. https://doi.org/10.1001/jama.285.19.2486.
[16] B.G. Nordestgaard, A. Varbo, Triglycerides and cardiovascular disease, The Lancet 384 (2014) 626–635. https://doi.org/10.1016/S0140-6736(14)61177-6.
[17] O.B. Samuels, G.J. Joseph, M.J. Lynn, H.A. Smith, M.I. Chimowitz, A standardized method for measuring intracranial arterial stenosis, AJNR Am. J. Neuroradiol. 21 (2000) 643–646.
[18] H.J.M. Barnett, D.W. Taylor, R.B. Haynes, D.L. Sackett, S.J. Peerless, G.G. Ferguson, A.J. Fox, R.N. Rankin, V.C. Hachinski, D.O. Wiebers, M. Eliasziw, Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis, N. Engl. J. Med. 325 (1991) 445–453. https://doi.org/10.1056/NEJM199108153250701.
[19] G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, E. Steiner, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, The Lancet 358 (2001) 2026–2033. https://doi.org/10.1016/S0140-6736(01)07098-2.
[20] K.C. Maki, M.H. Davidson, M.R. Dicklin, M. Bell, M. Witchger, S.B. Feinstein, Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease, J. Clin. Lipidol. 5 (2011) 141–151. https://doi.org/10.1016/j.jacl.2011.02.003.
[21] S. Biswas, P.K. Ghoshal, S.C. Mandal, N. Mandal, Association of low-density lipoprotein particle size and ratio of different lipoproteins and apolipoproteins with coronary heart disease, J. Cardiol. 52 (2008) 118–126. https://doi.org/10.1016/j.jjcc.2008.06.005.
[22] F.P. D'Armiento, A. Bianchi, F. de Nigris, D.M. Capuzzi, M.R. D'Armiento, G. Crimi, P. Abete, W. Palinski, M. Condorelli, C. Napoli, Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis, Stroke 32 (2001) 2472–2479.
[23] S. Marcovina, C.J. Packard, Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels, J. Intern. Med. 259 (2006) 437–446. https://doi.org/10.1111/j.1365-2796.2006.01648.x.
[24] X. Zhu, J.S. Parks, New Roles of HDL in Inflammation and Hematopoiesis, Annu. Rev. Nutr. 32 (2012). https://doi.org/10.1146/annurev-nutr-071811-150709.
[25] S.W. Kim, J.H. Jee, H.J. Kim, S.-M. Jin, S. Suh, J.C. Bae, S.W. Kim, J.H. Chung, Y.-K. Min, M.-S. Lee, M.-K. Lee, K.-W. Kim, J.H. Kim, Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1, Int. J. Cardiol. 168 (2013) 2678–2683. https://doi.org/10.1016/j.ijcard.2013.03.027.
[26] M.-R. Taskinen, P.J. Barter, C. Ehnholm, D.R. Sullivan, K. Mann, J. Simes, J.D. Best, S. Hamwood, A.C. Keech, Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes, Diabetologia 53 (2010) 1846–1855. https://doi.org/10.1007/s00125-010-1806-9.
[27] W. Zhao, W. Gong, N. Wu, Y. Li, K. Ye, B. Lu, Z. Zhang, S. Qu, Y. Li, Y. Yang, R. Hu, Association of lipid profiles and the ratios with arterial stiffness in middle-aged and elderly Chinese, Lipids Health Dis. 13 (2014) 37. https://doi.org/10.1186/1476-511X-13-37.
[28] A. Varbo, M. Benn, A. Tybjærg-Hansen, A.B. Jørgensen, R. Frikke-Schmidt, B.G. Nordestgaard, Remnant cholesterol as a causal risk factor for ischemic heart disease, J. Am. Coll. Cardiol. 61 (2013) 427–436. https://doi.org/10.1016/j.jacc.2012.08.1026.
[29] A. Varbo, M. Benn, B.G. Nordestgaard, Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment, Pharmacol. Ther. 141 (2014) 358–367. https://doi.org/10.1016/j.pharmthera.2013.11.008.
[30] R.-X. Zeng, S. Li, M.-Z. Zhang, X.-L. Li, C.-G. Zhu, Y.-L. Guo, Y. Zhang, J.-J. Li, Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes, J. Cardiol. 70 (2017) 113–120. https://doi.org/10.1016/j.jjcc.2016.12.010.
[31] A. Varbo, M. Benn, A. Tybjærg-Hansen, B.G. Nordestgaard, Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation, Circulation 128 (2013) 1298–1309. https://doi.org/10.1161/CIRCULATIONAHA.113.003008.